InflaRx N.V.
corporate_fare Company Profile
InflaRx N.V. (NASDAQ:IFRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for IFRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-03, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for IFRX spans 6-K, 424B5, 20-F.
Recent high-impact activity:
- InflaRx Maps Out Izicopan AAV Strategy: Two Phase 2 Trials in 2027, $1.5-2.0B Peak Sales Target
- InflaRx Q3 2026: Net Loss Narrows to €2.4M, Cash Runway Extended to End of 2029
- InflaRx Secures $140M in Offering, Extends Cash Runway to 2029, and Pursues Expanded AAV Strategy
- InflaRx Explores Expanded EU Strategy for AAV Drugs After Competitor's Setback
- InflaRx Eyes Expanded Europe Strategy for Vasculitis Drug After Competitor's EMA Setback
Financial Snapshot
Short Interest & Short Volume
15.02 days to coverFINRA reported short interest of 12,844,927 shares in IFRX as of the October 30, 2026 settlement, a 0.9% increase from the prior period — about 15.0 days to cover at its recent average daily volume. On November 20, 2026, 57.1% of IFRX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for IFRX, detected from its recent SEC filings · based on capital-structure filings through 2026-08-14.
ATM Registration · Remaining Capacity
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
IFRX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.